Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afamelanotide - Clinuvel Pharmaceuticals

Drug Profile

Afamelanotide - Clinuvel Pharmaceuticals

Alternative Names: [Nle4,DPhe7]-alpha-MSH; CUV-1647; EPT-1647; Melanotan I; Melanotan™; MT I; PRENUMBRA; Scenesse

Latest Information Update: 03 Feb 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Arizona
  • Developer Clinuvel Pharmaceuticals; Winhealth Pharma
  • Class Antiacnes; Antineoplastics; Antipyretics; Melanocyte-stimulating hormones; Peptides; Skin disorder therapies
  • Mechanism of Action Melanocortin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythropoietic protoporphyria; Pemphigus; Urticaria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythropoietic protoporphyria
  • Phase III Polymorphus light eruptions
  • Phase II Pemphigus; Vitiligo
  • Clinical Phase Unknown Xeroderma pigmentosum
  • Preclinical Unspecified
  • Suspended Urticaria
  • Discontinued Acne vulgaris; Actinic keratosis; Photodamage; Squamous cell cancer

Most Recent Events

  • 28 Oct 2020 Clinuvel Pharmaceuticals plans a phase IIa CUV801 trial for Stroke (Parenteral, Implant)
  • 27 Oct 2020 Registered for Erythropoietic protoporphyria (Prevention) in Australia (SC)
  • 26 Oct 2020 Adverse events data from a clinical trial (Special Access Program) in Xeroderma pigmentosum released by Clinuvel Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top